V VETTER
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

V VETTER Trademark

Serial Number: 85926577 • Registration: 4480276

V VETTER is a trademark filed by VETTER PHARMA-FERTIGUNG GMBH & CO. KG on May 8, 2013. The trademark is classified under Class 5 (Pharmaceuticals), Class 7 (Machinery), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

VETTER PHARMA-FERTIGUNG GMBH & CO. KG (15 trademarks)

2 SCHÜTZENSTR. 87 88212
RAVENSBURG , DE

Entity Type: 03

ARZNEIMITTEL GMBH APOTHEKER VETTER & CO. RAVENSBURG (23 trademarks)

IM KAMMERBRUHL 24
Ravensburg D-88212 , DE

Entity Type: 03

Trademark Details

Filing Date

May 8, 2013

Registration Date

February 11, 2014

Published for Opposition

November 26, 2013

Goods & Services

[ Machine tools, motors, couplings and clutches, drive belts, filling machines, labeling machines packaging machines, box-making machines ALL for erecting, filling and closing of cardboard and foldable boxes; machines for washing, filling and closing medical syringes and vials; INDUSTRIAL robots; mechanical transport machines for the transfer of containers between processing stations, and thermoforming machines for producing, filling and sealing of blister packaging; and machines for controlling the supply and filling of goods in containers ]

[ Pharmaceutical preparations and medicaments, solutions for oral use, sterile solutions and solutions for injections all for use in the treatment of infections, cancer, depression, heart disease, vascular disease, kidney disease, intestinal disorder, lung and bronchial disorder, liver dysfunction, oral and laryngeal disease, optical and cranial disorders; pharmaceutical preparations containing heparins, vaccines, calcitonins, prostaglandins, anaesthestics, reconstruction diluents, human growth hormone, monoclonal antibodies, epo, urokinase, factor VIII, gnrh analogs, and recombinant proteins eye drops, solutions for contact lenses all for use in the treatment of infections, cancer, depression, heart disease, vascular disease, kidney disease, intestinal disorder, lung and bronchial disorder, liver dysfunction, oral and laryngeal disease, optical and cranial disorders; fillings of liquid, semi-solid or solid substances, namely, pharmaceutical preparations in solvated form as solutions with active agents, as powders with solvent or as lyophilistates with solvent in injection systems, namely, in injection syringes and instruments for infections, injectors, injector pens as well as in single chamber, double chamber and disposable syringes, as well as solutions for oral use as well as sterile solutions, solutions for injections including aseptic filling of injection solutions all for use in the treatment of infections, cancer, depression, heart disease, vascular disease, kidney disease, intestinal disorder, lung and bronchial disorder, liver dysfunction, oral and laryngeal disease, optical and cranial disorders; preparations containing heparins, vaccines, calcitonins, prostaglandins, anaesthestics, reconstruction diluents, human growth hormone, monoclonal antibodies, epo, urokinase, factor VIII, gnrh analogs, and recombinant proteins all for use in the treatment of infections, cancer, depression, heart disease, vascular disease, kidney disease, intestinal disorder, lung and bronchial disorder, liver dysfunction, oral and laryngeal disease, optical and cranial disorders; tampons with and without disinfectants and bandages separately or jointly packed, and in sterile packages ]

Medical injection systems, namely, syringes and instruments for injections, injectors, injection pens auto-injectors as well as single chamber and double chamber disposable syringes, all sold empty; containers for medicaments made from glass and/or plastics and syringe holders for ready-to-use syringes for picking-up and handling of syringes

Design and development of injection syringes and instruments and injectors and corresponding packages; chemical and microbiological analyses for scientific and forensic research purposes

Filing History

NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Jan 24, 2024 NA89
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Jan 24, 2024 RNL1
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Jan 24, 2024 89AG
TEAS SECTION 8 & 9 RECEIVED
Jan 23, 2024 E89R
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Feb 11, 2023 REM2
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
May 6, 2020 ASCK
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Apr 29, 2020 ASGN
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Apr 3, 2020 NA85
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Apr 3, 2020 C15P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Apr 2, 2020 APRE
TEAS SECTION 8 & 15 RECEIVED
Feb 7, 2020 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Feb 11, 2019 REM1
REGISTERED-PRINCIPAL REGISTER
Feb 11, 2014 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 26, 2013 NPUB
PUBLISHED FOR OPPOSITION
Nov 26, 2013 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 6, 2013 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Oct 18, 2013 PREV
ASSIGNED TO LIE
Oct 17, 2013 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 2, 2013 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 2, 2013 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 2, 2013 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 2, 2013 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 2, 2013 CNEA
NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Aug 30, 2013 GEAN
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
Aug 30, 2013 GEAP
COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY
Aug 30, 2013 EPEN
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
Aug 30, 2013 CPEA
ASSIGNED TO EXAMINER
Aug 26, 2013 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
May 15, 2013 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 14, 2013 NWOS
NEW APPLICATION ENTERED
May 11, 2013 NWAP